close

Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Prenetics Global Ltd (NASDAQ: PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.89
+0.14 (0.05%)
AAPL  351.91
-0.87 (-0.25%)
AMD  503.41
-0.87 (-0.17%)
BAC  49.44
-0.64 (-1.28%)
GOOG  277.60
-3.66 (-1.30%)
META  618.87
-7.54 (-1.20%)
MSFT  506.24
-11.75 (-2.27%)
NVDA  155.46
-0.68 (-0.44%)
ORCL  115.00
-4.09 (-3.43%)
TSLA  380.11
+0.37 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.